EHA Library - The official digital education library of European Hematology Association (EHA)
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma | Future Oncology
ASCO News - Magrolimab in Combination with Azacitidine Demonstrates Durable Activity in Untreated MDS & AML | Leukemia and Lymphoma Society
New Research on Magrolimab Provides Key Insights as Gilead Rapidly Expands Research in AML | Leukemia and Lymphoma Society
Magrolimab - Multiple Myeloma Clinical Trials
Visual abstract | Azacitidine with venetoclax and magrolimab in patients with ND or R/R AML
New directions for emerging therapies in acute myeloid leukemia: the next chapter | Blood Cancer Journal
Magrolimab + Aza for AML - Slideset Download - Clinical Oncology 2022 | CCO
Frontiers | Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Forty Seven: Early Indications Suggest Magrolimab Could Be A Winner (NASDAQ:FTSV) | Seeking Alpha
FORTY SEVEN, INC.
Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients
EHA Library - The official digital education library of European Hematology Association (EHA)
Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia-CliniExpert
ENHANCE-3 Trial of Magrolimab in Combination with Venetoclax and Azacitidine in AML
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies | Business Wire
CD47-SIRPα Drug Target Minireview - Drug Hunter
EHA Library - The official digital education library of European Hematology Association (EHA)
Forty Seven (FTSV) On A Roll, Up Over 300% In 2 Months
Magrolimab for Solid Tumors Clinical Trial 2023 | Power
Magrolimab Achieving Positive Results in Phase 1b Trial of Untreated AML
Forty Seven: Buy The Dip In This CD47 Pioneer Ahead Of ASCO GI (NASDAQ:FTSV) | Seeking Alpha
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram
